Direct compression of acetylsalicylic acid for companion animal analgesia tablets begins with geometric dilution of the API into microcrystalline cellulose and lactose monohydrate in an IBC bin blender operating at 10 rpm for 15 minutes. The API fraction is presieved through an 850 µm stainless steel screen to remove agglomerates that form after storage above 40% RH. A two-stage blend is used: the first stage contains API, microcrystalline cellulose, and half of the lactose monohydrate; the second stage adds croscarmellose sodium at 2.0%–4.0% w/w and colloidal silicon dioxide at 0.5%–1.0% w/w. Magnesium stearate is added last at 0.5% w/w and blended for 3 minutes only. Longer lubrication times reduce tablet tensile strength and slow dissolution in 0.1 N hydrochloric acid. Compression on a 27-station rotary press at 8–15 kN produces tablets with hardness between 60 N and 100 N and friability below 1.0% according to USP <1216>. The finished scored tablets, typically 80 mg or 120 mg for dose adjustment in dogs, are tested for free salicylic acid by HPLC. Internal alert limits for free salicylic acid in uncoated veterinary tablets are commonly set at 0.3% unless stability data support a wider specification. Dissolution testing uses USP <711> Apparatus 2 at 75 rpm in 500 mL of 0.1 N hydrochloric acid, with a 30-minute sampling point. Tablets are packed in amber glass or PVC/PVDC blisters to limit moisture ingress to below 0.5 g/m²/day.

How Does Dry Granulation Preserve Acetylsalicylic Acid Potency Relative to Low-Shear Wet Granulation?

In low-shear wet granulation, contact of acetylsalicylic acid with water during binder addition initiates hydrolysis to salicylic acid and acetic acid. This is accelerated when granulating fluids exceed pH 3.0 and when drying temperatures are held too long. The preferred dry granulation route uses a roller compactor with 100 mm rolls and roll pressure between 20 bar and 40 bar. Acetylsalicylic acid is preblended with mannitol and a dry binder, then compacted into ribbons. The ribbons are milled through 1.0 mm and 0.8 mm screens to generate granule flow suitable for sachet filling or further tablet compression. The roller compaction process preserves free salicylic acid below the set internal limit of 0.3% by avoiding aqueous granulation entirely. For oral granules, the sieve fraction between 180 µm and 850 µm is retained to reduce segregation during filling. The terminal product is a sachet or bottle of oral granules containing 200 mg or 500 mg acetylsalicylic acid per unit dose. Dissolution is tested with the USP <711> basket apparatus at 50 rpm in 900 mL of water at 37°C. Uniformity of dosage units is assessed by USP <905>. Residual moisture is controlled to 1.0% or less by USP <921> Method Ia. The dry granulation process carries a known processing trade-off: densification can slow dissolution unless a disintegrant such as crospovidone at 2.0%–4.0% w/w is added extragranularly.

Because acetylsalicylic acid has a needle-like crystal habit and a bulk density in the range of 0.40–0.60 g/cm³, direct filling into hard gelatin capsules without densification creates unacceptable weight variability on automatic capsule machines. On dosator-type encapsulators, the powder bed height is maintained at 20–30 mm and pin compression is set at 5–10 mm to form a coherent slug before transfer into the capsule body. The API is first densified with microcrystalline cellulose by slugging or roller compaction, milled through a 1.0 mm screen, and then combined with crospovidone at 2.0%–4.0% w/w. Sodium stearyl fumarate at 0.5%–1.0% w/w is used as a lubrication agent where magnesium stearate causes excessive hydrophobicity on the slug surface. The fill weight is targeted to ±5% for size 0 or size 00 capsules. Terminal capsules are tested for dissolution using USP <711> Apparatus 2 at 75 rpm in 0.1 N hydrochloric acid. Content uniformity is measured by HPLC with acceptance criteria based on USP <905>. Packaging in cold-form aluminium blister strips instead of PVC alone limits moisture invasion and reduces free salicylic acid generation during shelf storage. Capsule formulations for veterinary use are less common than tablets because of the difficulty of dose adjustment in small dogs and cats; published data for this specific configuration is limited.

When Acetylsalicylic Acid Is Layered onto Calcium Carbonate Carriers for Medicated Premix Production

Premix manufacture begins with carrier selection because the API must remain uniformly distributed through bulk feed handling, auger transfer, and bag filling. Calcium carbonate with particle size between 100 µm and 300 µm is used as a dense, fracturable carrier that reduces segregation of acetylsalicylic acid in dry feed. Stepwise geometric dilution from a 1:1 ratio through 1:3, 1:7, and 1:9 stages produces a final premix concentration of 10% w/w. A ribbon blender running at 14 rpm for 20 minutes after each addition prevents localized API pockets and poor assay distribution. The final premix is screened through 850 µm to remove soft aggregates. Mineral oil at 0.5% w/w may be added after the active is fully extended to reduce dust and electrostatic charge. The terminal product is packed in 25 kg polyethylene-lined paper bags. In jurisdictions where salicylic acid residues are regulated, depletion studies and withdrawal periods must be based on the actual feed inclusion rate and animal-specific pharmacokinetic data. Blend uniformity is tested by near-infrared or HPLC on ten batch samples, with acceptance criteria of ±10% of label claim. Final feed homogeneity depends on carrier particle size distribution and moisture content below 2.0%. Equipment surfaces are checked for carryover because acetylsalicylic acid can adhere electrostatically to non-grounded transfer piping.

Dissolved Oxygen, pH Drift, and Conservation of Acetylsalicylate in Drinking Water Systems

Preparation of acetylsalicylic acid stock solutions for drinking water medication is constrained by the free acid aqueous solubility of approximately 3.3 mg/mL at 25°C and by pH-dependent hydrolysis. To achieve higher concentrations, sodium bicarbonate or sodium citrate is added to convert the acid to the more soluble acetylsalicylate salt in situ. The reaction must be controlled because the resulting solution has a pH closer to 6.0–6.5, where hydrolysis accelerates relative to the free acid stability maximum near pH 2.5–3.5. Stock solutions are prepared in stainless steel or high-density polyethylene tanks and diluted to the final medicated water concentration required for the target species. Low-shear impellers and minimal vortex are specified because aeration and dissolved oxygen increase free salicylic acid formation. A single batch should not be held for more than 24 hours unless stability data support longer use periods. The terminal product is a medicated drinking water delivered through a proportioner or in-line dosing pump calibrated to inject the approved volume per 1000 L of water. Content uniformity is assessed by HPLC using a validated method based on USP <621>, and pH is measured by USP <791>. In practice, drinking water delivery of acetylsalicylic acid is highly sensitive to source water alkalinity, chloride content, and microbial load because these factors shift pH and accelerate degradation. Published data for specific field water matrices are limited, so each farm supply should be characterized before batch release.

Aseptic dry-fill of micronized acetylsalicylic acid into siliconized glass vials avoids the hydrolytic ring opening that accompanies terminal steam sterilization at 121°C. Terminal moist heat is not applicable because acetylsalicylic acid degrades rapidly in aqueous media. Gamma irradiation may generate free radicals and elevate free salicylic acid levels. Aseptic processing is therefore the only viable route for a sterile dry powder of the free acid. The API is processed under Grade A laminar airflow with Grade B background, filled into depyrogenated vials, and sealed immediately. Reconstitution with Water for Injections produces a suspension rather than a true solution because the free acid solubility is insufficient to reach therapeutic doses in small injection volumes. The final product may be specified as a sterile suspension for injection containing 250 mg acetylsalicylic acid per vial. Polysorbate 80 at 0.1% w/w can be included in the dry fill to improve wetting of the hydrophobic API after reconstitution. Quality release includes USP <71> sterility testing, USP <85> bacterial endotoxin testing, USP <788> particulate matter, and USP <790> visible particulate inspection. The injectable route is reserved for acute conditions where oral administration is not feasible or rapid onset is required. Long-term stability of the reconstituted suspension is limited by hydrolysis; the product is intended for administration immediately after reconstitution.

Metering Sodium Bicarbonate and Citric Acid Sustains the Dissolution Front in Acetylsalicylic Acid Effervescent Granules

Effervescent granule production uses an organic-solvent granulation or dry compaction route because the presence of free moisture triggers premature acid-base reaction between acetylsalicylic acid, citric acid, and sodium bicarbonate. The effervescent couple is proportioned so that dissolution produces a buffered solution with final pH 5.5–6.5. A commonly used ratio is 1 part citric acid to 2 parts sodium bicarbonate by mass, adjusted for the acid value of the active. After dry mixing in a tumbling blender, the blend is compacted in a roll press at 20–30 kN, milled to 0.5–1.0 mm, and immediately filled into aluminium foil sachets with desiccant. Residual moisture is held below 0.5% by Karl Fischer titration according to USP <921> Method Ia. The terminal product is a granule that dissolves in 200 mL of water within 2 minutes. Packaging must have moisture vapour transmission rates below 0.1 g/m²/day to prevent caking and loss of effervescent action. Dissolution testing of the granules is performed in 900 mL of water at 37°C with a 50-rpm basket apparatus. Particle size retention between 180 µm and 850 µm is monitored by USP <786>. The process design must account for the exothermic reaction during dissolution and the potential for carbon dioxide release to alter local pH before the active is fully dissolved.